開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT
ENROLLMENT OF FIRST PATIENT AND INITIATION OF PHASE III CLINICAL TRIAL OF KX-826 FOR TREATMENT OF AGA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") is pleased to announce that the Company has on 31 December 2021 enrolled and dosed the first patient in the phase III clinical trial (the "**Phase III Clinical Trial**") of pyrilutamide ("**KX-826**"), its in-house developed and potential first-in-class topical drug globally, for the treatment of male androgenetic alopecia (AGA) patients. On 24 November 2021, the Company announced the National Medical Products Administration (NMPA) greenlighted the Investigational New Drug (IND) application for the pivotal phase III study of KX-826. KX-826 is the first androgen receptor (AR) antagonist that has entered the pivotal phase III clinical trial for AGA treatment in China and globally.

On 20 December 2021, the investigator meeting for the Phase III Clinical Trial was successfully held. Peking University People's Hospital and Huashan Hospital of Fudan University led the trial, with 26 hospitals to be participating. After successfully co-leading the phase II clinical trial of KX-826 in China for the treatment of AGA, Professor Zhang Jianzhong from Peking University People's Hospital and Professor Yang Qinping from Huashan Hospital of Fudan University cooperate again to be the leading principal investigators (leading PIs) of the pivotal Phase III Clinical Trial of KX-826.

The pivotal study is a randomized, double-blind, placebo-controlled, multi-regional phase III clinical trial designed to evaluate the efficacy and safety of KX-826 for treating male AGA patients in China. The phase III sample size is 416, and the trial duration is 24 weeks. The primary endpoint for the clinical trial is the change from baseline in non-vellus target area hair count (TAHC) at the end of week 24.

For further details, please refer to the announcement of the Company dated 24 November 2021.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that pyrilutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 2 January 2022

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*